ArriVent BioPharma (AVBP) Institutional Ownership $24.50 +0.90 (+3.81%) Closing price 04:00 PM EasternExtended Trading$24.49 -0.01 (-0.02%) As of 05:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for ArriVent BioPharma (NASDAQ:AVBP)CurrentInstitutional OwnershipPercentage9.48%Number ofInstitutional Buyers(last 12 months)45TotalInstitutional Inflows(last 12 months)$115.48MNumber ofInstitutional Sellers(last 12 months)11TotalInstitutional Outflows(last 12 months)$9.53M Get AVBP Insider Trade Alerts Want to know when executives and insiders are buying or selling ArriVent BioPharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data AVBP Institutional Buying and Selling by Quarter ArriVent BioPharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/19/2025 Jane Street Group LLC10,200$189K0.0%N/A0.030% 5/16/2025 Woodline Partners LP146,373$2.71M0.0%+0.4%0.428% 5/16/2025 Goldman Sachs Group Inc.76,877$1.42M0.0%-62.9%0.225% 5/16/2025 Dynamic Technology Lab Private Ltd14,379$266K0.0%N/A0.042% 5/16/2025 Infinitum Asset Management LLC2,066,238$38.21M12.4%+25.7%6.039% 5/14/2025 Rafferty Asset Management LLC17,409$322K0.0%-36.2%0.051% 5/14/2025 Wellington Management Group LLP61,348$1.13M0.0%+46.3%0.180% 5/12/2025 Nuveen LLC44,282$819K0.0%N/A0.130% 5/9/2025 Deutsche Bank AG23,183$429K0.0%-3.9%0.068% 5/9/2025 Charles Schwab Investment Management Inc.196,494$3.63M0.0%-4.8%0.577% Get the Latest News and Ratings for AVBP and Related StocksEnter your email address below to receive the latest news and analysts' ratings for ArriVent BioPharma and its competitors with MarketBeat's FREE daily newsletter. 5/9/2025 Vanguard Group Inc.1,503,358$27.80M0.0%+6.1%4.416% 4/30/2025 Alps Advisors Inc.25,167$465K0.0%-7.7%0.074% 4/15/2025 SG Americas Securities LLC22,680$419K0.0%+92.1%0.067% 4/7/2025 GAMMA Investing LLC2,681$500K0.0%+3,730.0%0.008% 3/24/2025 Wellington Management Group LLP41,921$1.12M0.0%N/A0.123% 3/18/2025 California State Teachers Retirement System13,649$364K0.0%+561.3%0.040% 2/26/2025 Infinitum Asset Management LLC1,643,923$43.79M23.1%N/A4.878% 2/17/2025 UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC8,165$218K0.0%N/A0.024% 2/17/2025 Woodline Partners LP145,797$3.88M0.0%+20.5%0.433% 2/17/2025 Suvretta Capital Management LLC2,246,000$59.83M2.0%+21.7%6.665% 2/17/2025 Rafferty Asset Management LLC27,299$727K0.0%+186.3%0.081% 2/17/2025 ProShare Advisors LLC9,532$254K0.0%N/A0.028% 2/17/2025 Octagon Capital Advisors LP2,059,387$54.86M9.0%+4.2%6.111% 2/17/2025 Millennium Management LLC52,545$1.40M0.0%-75.7%0.156% 2/17/2025 MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.17,114$456K0.0%+8.4%0.051% 2/17/2025 Deutsche Bank AG24,136$643K0.0%+57.4%0.072% 2/17/2025 Bank of America Corp DE45,544$1.21M0.0%+5.3%0.135% 2/17/2025 BNP Paribas Financial Markets3,300$88K0.0%-85.0%0.010% 2/14/2025 Novo Holdings A S1,520,627$40.51M2.5%+1.0%4.512% 2/14/2025 Northern Trust Corp241,009$6.42M0.0%+4.6%0.715% 2/14/2025 Virtus ETF Advisers LLC2,747$73K0.0%N/A0.008% 2/14/2025 Voya Investment Management LLC8,373$223K0.0%N/A0.025% 2/14/2025 Price T Rowe Associates Inc. MD10,965$293K0.0%+17.3%0.033% 2/14/2025 Tower Research Capital LLC TRC1,599$43K0.0%+773.8%0.005% 2/14/2025 MetLife Investment Management LLC17,460$465K0.0%+6.8%0.052% 2/13/2025 Barclays PLC53,499$1.43M0.0%+28.8%0.159% 2/13/2025 Legal & General Group Plc13,627$363K0.0%+379.1%0.040% 2/13/2025 Invesco Ltd.15,339$409K0.0%N/A0.046% 2/13/2025 Wells Fargo & Company MN14,493$386K0.0%+40.0%0.043% 2/12/2025 Geode Capital Management LLC596,182$15.89M0.0%-0.2%1.769% Get Ready for Elon Musk’s BIGGEST Comeback Yet (Ad)Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough. Click here to see why Tesla's about to prove everyone wrong... again.2/12/2025 Wellington Management Group LLP41,921$1.12M0.0%N/A0.124% 2/12/2025 JPMorgan Chase & Co.15,685$418K0.0%+26.0%0.047% 2/11/2025 Corebridge Financial Inc.14,007$373K0.0%-7.0%0.042% 2/11/2025 Vanguard Group Inc.1,417,291$37.76M0.0%+5.3%4.206% 2/11/2025 KLP Kapitalforvaltning AS3,100$83K0.0%N/A0.009% 2/11/2025 Intech Investment Management LLC14,798$394K0.0%N/A0.044% 2/10/2025 Swiss National Bank26,400$703K0.0%N/A0.078% 2/6/2025 Charles Schwab Investment Management Inc.206,379$5.50M0.0%+2.0%0.612% 1/31/2025 New York State Common Retirement Fund7,783$207K0.0%+34.6%0.023% 1/30/2025 Rhumbline Advisers36,690$977K0.0%+9.1%0.109% 1/27/2025 Mirae Asset Global Investments Co. Ltd.1,123$31K0.0%N/A0.003% 1/24/2025 China Universal Asset Management Co. Ltd.7,145$190K0.0%N/A0.021% 12/26/2024 JPMorgan Chase & Co.12,445$292K0.0%+183.2%0.037% 11/19/2024 Barclays PLC41,522$976K0.0%+1,124.8%0.123% 11/16/2024 Geode Capital Management LLC597,165$14.04M0.0%+154.2%1.778% 11/15/2024 Barclays PLC41,522$976K0.0%+1,124.8%0.124% 11/15/2024 Jane Street Group LLC10,626$250K0.0%-30.7%0.032% 11/15/2024 State Street Corp476,809$11.21M0.0%+210.4%1.419% 11/14/2024 Suvretta Capital Management LLC1,845,162$43.36M1.4%+7.7%5.493% 11/14/2024 MetLife Investment Management LLC16,350$384K0.0%+168.9%0.049% 11/13/2024 BNP Paribas Financial Markets21,965$516K0.0%+32.6%0.065% 11/13/2024 FMR LLC2,119,695$49.81M0.0%+8.7%6.310% 11/13/2024 The Manufacturers Life Insurance Company10,234$240K0.0%N/A0.030% 11/12/2024 Charles Schwab Investment Management Inc.202,368$4.76M0.0%+153.8%0.602% 10/30/2024AlphaCentric Advisors LLC15,000$352K0.3%-82.6%0.045% 10/24/2024 Novo Holdings A S1,505,315$35.38M1.8%+0.4%4.494% 10/3/2024 SG Americas Securities LLC11,927$280K0.0%N/A0.036% 8/20/2024 Novo Holdings A S1,500,000$27.83M1.4%+39.3%4.478% 8/1/2024 Rhumbline Advisers12,707$236K0.0%+30.1%0.038% 7/26/2024 Bank of New York Mellon Corp29,847$554K0.0%+31.4%0.089% 7/26/2024AlphaCentric Advisors LLC86,000$1.60M1.2%+3.6%0.257% 5/24/2024 Farallon Capital Management LLC151,768$2.71M0.0%N/A0.453% 5/16/2024 Blackstone Inc.25,000$446K0.0%N/A0.075% 5/15/2024 Hhlr Advisors LTD.3,929,117$70.17M1.5%N/A11.732% 5/15/2024Altitude Crest Partners Inc.555,555$9.92M4.2%N/A1.659% 5/14/2024 American International Group Inc.4,845$87K0.0%N/A0.014% 5/10/2024 Vanguard Group Inc.648,735$11.59M0.0%N/A1.937% 5/1/2024 BNP Paribas Financial Markets4,659$83K0.0%N/A0.014% (Data available from 1/1/2016 forward) AVBP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of AVBP shares? During the previous two years, 54 institutional investors and hedge funds held shares of ArriVent BioPharma. The most heavily invested institutionals were Hhlr Advisors LTD. ($70.17M), Suvretta Capital Management LLC ($59.83M), Octagon Capital Advisors LP ($54.86M), FMR LLC ($49.81M), Novo Holdings A S ($40.51M), Infinitum Asset Management LLC ($38.21M), and Vanguard Group Inc. ($27.80M).Learn more on AVBP's institutional investors. What percentage of ArriVent BioPharma stock is owned by institutional investors? 9.48% of ArriVent BioPharma stock is owned by institutional investors. Learn more on AVBP's institutional investor holdings. Which institutional investors have been buying ArriVent BioPharma stock? Of the 50 institutional investors that purchased ArriVent BioPharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Hhlr Advisors LTD. ($3.93M), Infinitum Asset Management LLC ($2.07M), Vanguard Group Inc. ($806.54K), Altitude Crest Partners Inc. ($555.56K), Suvretta Capital Management LLC ($533.30K), Novo Holdings A S ($443.49K), and Geode Capital Management LLC ($362.22K). How much institutional buying is happening at ArriVent BioPharma? Institutional investors have bought a total of 10,119,681 shares in the last 24 months. This purchase volume represents approximately $210.49M in transactions. Which ArriVent BioPharma major shareholders have been selling company stock? Of the 11 institutional investors that sold ArriVent BioPharma stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Millennium Management LLC ($164.09K), Goldman Sachs Group Inc. ($130.39K), AlphaCentric Advisors LLC ($71K), BNP Paribas Financial Markets ($18.67K), Rafferty Asset Management LLC ($9.89K), Charles Schwab Investment Management Inc. ($9.89K), and Jane Street Group LLC ($4.71K). How much institutional selling is happening at ArriVent BioPharma? Institutional investors have sold a total of 413,702 shares in the last 24 months. This volume of shares sold represents approximately $9.53M in transactions. Related Companies MoonLake Immunotherapeutics Institutional Ownership Catalyst Pharmaceuticals Institutional Ownership Metsera Institutional Ownership Crinetics Pharmaceuticals Institutional Ownership Viking Therapeutics Institutional Ownership MorphoSys Institutional Ownership Scholar Rock Institutional Ownership Immunovant Institutional Ownership HUTCHMED Institutional Ownership Apellis Pharmaceuticals Institutional Ownership This page (NASDAQ:AVBP) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredGet Ready for Elon Musk’s BIGGEST Comeback YetTesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ArriVent BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ArriVent BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
